| scholarly article | Q13442814 |
| P50 | author | Niels Reinmuth | Q92140332 |
| Maciej Bryl | Q92805623 | ||
| P2093 | author name string | Igor Bondarenko | |
| Vladimir Vladimirov | |||
| Kostas Syrigos | |||
| Kazuo Kasahara | |||
| Katherine Liau | |||
| Fiona Hilton | |||
| Angel H Bair | |||
| Manuela Zereu | |||
| P2860 | cites work | Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab | Q88159233 |
| Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | Q88973544 | ||
| Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study | Q90928646 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Improved survival with bevacizumab in advanced cervical cancer | Q33566222 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications | Q34569994 | ||
| Vascular endothelial growth factor as a target for anticancer therapy | Q35792723 | ||
| A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers | Q36762864 | ||
| Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey | Q37731321 | ||
| Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. | Q38383854 | ||
| Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars | Q38643555 | ||
| CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial | Q39358281 | ||
| The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours | Q39512984 | ||
| Comparative analysis of two rates | Q41501755 | ||
| Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer | Q42632045 | ||
| Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. | Q48619267 | ||
| American Society of Clinical Oncology Statement: Biosimilars in Oncology | Q50004273 | ||
| Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. | Q54135887 | ||
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57051777 | ||
| Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial | Q57110471 | ||
| Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial | Q58565563 | ||
| P433 | issue | 5 | |
| P921 | main subject | bevacizumab | Q413299 |
| carboplatin | Q415588 | ||
| paclitaxel | Q423762 | ||
| P304 | page(s) | 555-570 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | BioDrugs | Q4914612 |
| P1476 | title | PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study | |
| P478 | volume | 33 |
| Q92953557 | Inhaled chemotherapy adverse effects: mechanisms and protection methods | cites work | P2860 |
Search more.